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The current American Heart Association guidelines recom-mend a score of 2B or more on the modified Thrombolysis 
in Cerebral Infarction (mTICI) scale as the angiographic goal 
of endovascular treatment (EVT) for acute ischemic stroke 
of the anterior circulation.1 The most recent European Stroke 
Organisation—European Society for Minimally Invasive 
Neurological Therapy guidelines also define successful reper-
fusion as a TICI score of 2B or 3, although expert opinion 
states that interventionists should aim for TICI grade 3 reper-
fusion.2 The mTICI 2B/3 target is based on the threshold used 
in the thrombectomy trials that established EVT as standard 
care.3 However, already in 2005, an additional 2C grade was 
introduced to the TICI scale, to identify those cases with near-
perfect angiographic results.4 This addition was later termed 
the extended TICI (eTICI) scale, with eTICI 2C defined as 
near-complete perfusion except for slow flow in a few distal 
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cortical vessels or presence of small distal cortical emboli, a 
category which is now widely implemented.5
Patients with eTICI 2C, generally scored as 90% to 99% 
reperfusion of the target downstream territory on digital 
subtraction angiography (DSA),6 show more angiographic 
similarities to mTICI 3 patients (ie, patients with 100% reper-
fusion) than to mTICI 2B patients (patients with 50%–89% 
reperfusion). From this observation, one would expect that 
patients with eTICI 2C have a clinical outcome that more 
closely resembles that of patients with eTICI 3 than that of 
patients with eTICI 2B. A few studies have previously inves-
tigated the relation between various eTICI scores and clinical 
outcome.6–10 The results of these studies varied, which may be 
due to variations in definitions and the fact that some studies 
had a small sample size.7–10 Moreover, some studies used clin-
ical trial data,6 which may not reflect daily clinical practice.
We aimed to investigate the association between clinical 
outcome and scores on the eTICI scale, specifically focusing 
on scores 2B, 2C, and 3, using data of a nationwide cohort 
representing daily clinical practice.11
Methods
Data will not be made available to other researchers, as no patient 
approval was obtained for sharing coded data. However, syntax and 
output files of statistical analyses may be made available via secured 
download link on request to the corresponding author.
Design and Study Population
We used data from the Multicenter Randomized Clinical Trial 
of Endovascular Treatment for Acute Ischemic Stroke in the 
Netherlands (MR CLEAN) Registry part 1 and 2, a prospective, 
nationwide registry of consecutive patients undergoing EVT in the 
Netherlands who were treated between March 2014 and November 
2017.11,12 We included adult patients with a large vessel occlusion 
of the anterior circulation (internal carotid artery [ICA/ICA-T], 
middle cerebral artery [M1/M2], or anterior cerebral artery [A1/
A2]) confirmed on CT angiography, who had both antero-posterior 
and lateral DSA runs postreperfusion, as reperfusion grade can only 
be reliably assessed with 2 planes.13 All patients received intrave-
nous recombinant tissue-type plasminogen activator (IV r-tPA; 0.9 
mg/kg alteplase over 1 hour with 10% initial bolus) unless contra-
indicated, according to national guidelines.14
An imaging core laboratory adjudicated all patient imaging. The 
members of the core lab were blinded to all clinical data except for 
symptom side. Reperfusion grade was measured according to the 
eTICI scale on final DSA, as compared with initial DSA. In case the 
initial angiographic run did not show a target occlusion anymore, a 
minimum eTICI score of 2B was assigned. For patients in whom the 
target occlusion was not accessible, for example, due to elongation 
of the carotid artery or aortic arch, treatment was considered unsuc-
cessful and these patients were assigned reperfusion grade eTICI 
0. Safety outcome measures were scored by a complication com-
mittee whose members were blinded to treatment center. A central 
medical ethics committee granted permission to perform the study 
as a registry.
Outcome Measures
We compared functional outcome at 90 days as measured by the dis-
tribution on the modified Rankin Scale (mRS) across the eTICI cat-
egories. Patients with eTICI 0 or eTICI 1 were collapsed into a single 
category. Other outcome measures were functional independence at 
90 days (mRS 0–2); all-cause mortality at 90 days; and symptomatic 
intracranial hemorrhage (sICH). Intracranial hemorrhage was consid-
ered symptomatic if patients died or deteriorated neurologically (a 
decline of at least 4 points on the National Institutes of Health Stroke 
Scale), and the hemorrhage was related to the clinical deterioration 
(according to the Heidelberg Bleeding Classification15).
Statistical Analysis
Baseline and treatment characteristics were analyzed using standard 
statistics. We estimated the odds ratio (OR) for a shift towards better 
functional outcome using ordinal logistic regression analysis for each 
reperfusion grade, using the eTICI 2B patient group as the reference 
group. Similarly, we estimated the OR for functional independence at 
90 days, mortality at 90 days, and sICH for each reperfusion grade as 
compared with eTICI 2B patients with logistic regression analyses. 
We further performed a shift analysis to estimate the common OR 
for a better functional outcome for every step increase on the eTICI 
scale. In a sensitivity analysis, we estimated the common OR for bet-
ter functional outcome for every step increase on the eTICI scale, 
after excluding patients with eTICI 2B or better on initial angiog-
raphy. In this subgroup, we also compared functional outcome be-
tween patients with eTICI 2C and those with eTICI 2B, and between 
patients with eTICI 3 and eTICI 2B.
For mRS at 90 days, functional independence, and mortality 
at 90 days, we adjusted for age, baseline National Institutes of 
Health Stroke Scale score, collateral status,16 IV r-tPA before 
EVT, systolic blood pressure at baseline, time of symptom onset 
to groin puncture, occlusion location and use of general anes-
thesia. For sICH, we adjusted for baseline National Institutes of 
Health Stroke Scale score, collateral status, IV r-tPA before EVT, 
systolic blood pressure at baseline, and time of symptom onset to 
groin puncture.
To further assess whether outcomes were significantly better in 
patients with eTICI 3 than in patients with eTICI 2C, we compared a 
model with eTICI 2C and eTICI 3 combined, to a model with eTICI 
3 as a separate category based on the likelihood ratio test. Lastly, we 
assessed the reperfusion grades as scored by local operating physi-
cians (who applied the mTICI scale) versus those scored by the core 
laboratory (who applied the eTICI scale) for descriptive purposes, 
although we could not make a formal comparison due to differences 
in grading scales.
Adjusted (common) ORs (a[c]ORs) are reported with 95% CI, 
and all P values are 2-sided. Multiple imputation was performed for 
missing data based on relevant covariates and outcome. Statistical 
analyses were performed with IBM Statistics for Windows, Version 
25.0 and graphics were made using the computing environment R (R 
Development Core Team, 2013).
Results
In total, 3637 patients were included in the MR CLEAN 
Registry. We excluded 830 patients (23%), mostly because 
they did not meet imaging criteria (Figure 1). Of the remaining 
2807 patients, 470 (17%) achieved reperfusion grade eTICI 0 
to 1, 404 (14%) eTICI 2A, 700 (25%) eTICI 2B, 340 (12%) 
eTICI 2C, and 893 (32%) eTICI 3.
Baseline characteristics per eTICI grade are reported in 
the Table. Median age tended to decrease with increasing re-
perfusion grade (ranging from 75 years to 71 years, P<0.001). 
Onset to groin times were slightly shorter in patients with 
higher reperfusion grades (ranging from 203 minutes to 190 
minutes, P=0.16). The distribution of occlusion location on 
baseline computed tomography angiography differed per 
eTICI grade (P<0.01). Patients with eTICI 2C more often 
underwent general anesthesia compared with other groups 
(eTICI 0–1 22%; eTICI 2A 21%; eTICI 2B 26%; eTICI 2C 
37%; eTICI 3 29%; P<0.001). Rates of IV rtPA before EVT 
did not differ between groups. There was a clear decline in 
duration of procedure as reperfusion grade increased, ranging 
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from median 68 minutes for eTICI 0 to 1 patients to 45 min-
utes for eTICI 3 patients (P<0.001).
There was an overall positive association between reper-
fusion grade and functional outcome at 90 days (acOR for a 
shift on the mRS per step on the eTICI scale 1.34 [95% CI, 
1.28–1.41], Figure 2). When compared with patients with 
eTICI 2B, patients with eTICI 2C had higher odds for bet-
ter functional outcome, although this difference did not reach 
statistical significance (acOR, 1.22 [95% CI, 0.96–1.57]; 
Figure 3A). Patients with eTICI 3 did have a statistically sig-
nificant better functional outcome compared with those with 
eTICI 2B (acOR, 1.33 [95% CI, 1.09–1.62]). We found a sim-
ilar trend for functional independence (Figure 3B), as well as 
a decrease in risk of mortality and sICH with increasing reper-
fusion grades (Figure 3C and 3D).
In a sensitivity analysis excluding patients with eTICI 2B 
or better on initial angiography, the positive association be-
tween reperfusion grade and functional outcome at 90 days 
remained significant (acOR, 1.28 [95% CI, 1.22–1.33]; Figure 
I in the Data Supplement). Moreover, patients with eTICI 2C 
had a statistically significantly better functional outcome than 
those with eTICI 2B (acOR, 1.40 [95% CI, 1.10–1.78]), as 
did patients with eTICI 3 (acOR, 1.55 [95% CI, 1.26–1.91]).
However, when comparing a model with eTICI 2C and 
eTICI 3 scores combined, to a model with eTICI 3 as a sepa-
rate category, a likelihood test showed that the model fit with 
eTICI 3 as a separate category was not significantly better than 
the model fit with eTICI 2C and eTICI 3 combined (P=0.47).
Lastly, local operating physicians appeared to more often 
assign a score of mTICI 3 than core laboratory observers 
assigned eTICI 3 (46.9% versus 31.8%, respectively; Table I 
in the Data Supplement).
Discussion
We found that increasing scores on the eTICI scale are associ-
ated with better clinical outcomes after EVT in patients with 
stroke. Given the angiographic proximity of eTICI 2C and 3, 
we had expected that outcomes for patients with these scores 
would closely resemble each other. However, our results do 
not seem to substantiate this hypothesis. All outcomes appear 
to gradually improve per eTICI score, with eTICI 3 patients 
having the best outcomes. This suggests that, contrary to 
guideline recommendations,1 interventionists should not settle 
for eTICI 2B, a notion which is supported by expert opinion.2 
However, it remains unclear whether extending the procedure 
with additional thrombectomy attempts safely leads to higher 
reperfusion grades.
Previous studies did find that patients with eTICI 2C had 
outcomes closely resembling those of eTICI 3 patients.7,8,10 
However, the statistical power of these studies may have been 
too small to detect a true difference between eTICI 2C and 
eTICI 3 patients, and only one study employed an independent 
core laboratory to evaluate imaging.8 It is thus conceivable 
that some patients were incorrectly scored as eTICI 3, when 
they really still had a few distal emboli, leading to distortion 
of groups.17 Other, older studies observed a clear threshold of 
mTICI 2B as the best predictor for functional independence at 
90 days,18,19 but this might be explained by the fact that these 
older studies did not include a separate 2C category. A recent 
meta-analysis6 also found an incremental association between 
eTICI score and clinical outcome, as we did. However, these 
results were based on data from clinical trials, which likely 
represent a biased patient group with favorable clinical and 
imaging characteristics. Moreover, in a sensitivity analysis in 
our study excluding patients with eTICI 2B or better on initial 
Figure 1. Flowchart of patient selection. eTICI indicates extended Thrombolysis in Cerebral Infarction; and MR CLEAN, Multicenter Randomized Clinical Trial 
of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands.
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angiography, the overall association between increasing reper-
fusion grade and better functional outcome remained statisti-
cally significant. Therefore, our results add to current literature 
as they further support this association in a cohort reflecting 
daily clinical practice, whilst applying the eTICI scale.
There are several potential explanations why patients 
with eTICI 2C do not follow a similar clinical course to that 
of patients with eTICI 3. First, it could indicate that eTICI 
2C actually heralds irreversible tissue damage due to im-
paired microvascular reperfusion despite recanalization of 
Table. Baseline Characteristics of Patients per eTICI Category
Characteristic eTICI 0–1 (n=470) eTICI 2A (n=404) eTICI 2B (n=700) eTICI 2C (n=340) eTICI 3 (n=893) P Value
Clinical data
  Age 75 (65–83) 72 (61–81) 71 (60–80) 71 (60–79) 71 (61–80) <0.001
  Men 240/470 (51) 208/404 (52) 356/700 (51) 185/340 (54) 472/883 (53) 0.80
  Transferred from primary stroke center 262/470 (56) 214/404 (53) 376/700 (54) 175/340 (52) 514/892 (58) 0.25
  Time symptom onset to groin puncture* 200 (150–272) 203 (150–263) 200 (150–260) 195 (148–260) 190 (150–245) 0.16
  NIHSS† 16 (11–19) 16 (12–20) 15 (10–19) 16 (11–20) 16 (11–20) 0.02
  SBP, mm Hg‡ 150 (135–166) 152 (133–170) 148 (130–166) 150 (133–167) 146 (130–162) <0.01
  DBP, mm Hg§ 84 (75–94) 83 (72–91) 82 (70–91) 80 (73–93) 80 (70–90) <0.01
Medical history
  Atrial fibrillation 135/462 (29) 101/400 (25) 139/690 (20) 89/337 (26) 199/880 (23) <0.01
  Diabetes mellitus 80/465 (17) 65/402 (16) 101/693 (15) 64/339 (19) 151/888 (17) 0.46
  Hypertension 242/459 (53) 211/397 (53) 345/679 (51) 175/336 (52) 462/876 (53) 0.94
  Ischemic stroke 83/466 (18) 70/402 (17) 114/693 (17) 59/340 (17) 139/885 (16) 0.86
  Prestroke mRS 0–1 358/457 (78) 312/395 (79) 546/681 (80) 274/333 (82) 722/875 (83) 0.30
  Use of oral anticoagulation 99/467 (21) 59/401 (15) 90/692 (13) 57/340 (17) 139/886 (16) <0.01
  Antiplatelet use 141/466 (30) 125/398 (31) 203/686 (30) 114/339 (34) 289/882 (33) 0.58
Imaging and treatment characteristics
  ASPECTS‖ 9 (8–10) 9 (7–10) 9 (7–10) 9 (8–10) 9 (8–10) 0.20
  Clot burden score¶ 6 (4–8) 6 (4–8) 6 (4–8) 6 (4–8) 6 (4–8) 0.11
  Collateral status 0.61
   Absent collaterals 26/430 (6) 29/387 (8) 38/653 (6) 21/320 (7) 42/846 (5)  
   Poor collaterals 158/430 (37) 132/387 (34) 236/653 (36) 120/320 (38) 297/846 (35)  
   Moderate collaterals 167/430 (39) 144/387 (37) 260/653 (40) 130/320 (41) 328/846 (39)  
   Good collaterals 79/430 (18) 82/387 (21) 119/653 (18) 49/320 (15) 179/846 (21)  
  Occlusion location on CTA <0.01
   ICA 30/438 (7) 27/393 (7) 30/670 (5) 15/327 (5) 35/873 (4)  
   ICA-T 96/438 (22) 89/393 (23) 129/670 (19) 75/327 (23) 172/873 (20)  
   Proximal M1 98/438 (22) 78/393 (20) 157/670 (23) 99/327 (30) 233/873 (27)  
   Distal M1 131/438 (30) 144/393 (37) 235/670 (35) 100/327 (31) 309/873 (35)  
   M2 78/438 (18) 53/393 (14) 112/670 (17) 38/327 (12) 112/873 (13)  
   Other (M3/anterior) 5/438 (1) 2/393 (1) 7/670 (1) 0/327 (0) 12/873 (1)  
  Location of stroke in left hemisphere 251/469 (54) 201/404 (50) 382/700 (55) 183/340 (54) 468/893 (52) 0.48
  IV rtPA 344/468 (74) 300/402 (75) 535/697 (77) 246/339 (73) 676/889 (76) 0.51
  General anesthesia 95/424 (22) 81/387 (21) 172/652 (26) 119/322 (37) 249/862 (29) <0.001
  Procedure time# 68 (45–94) 75 (55–105) 54 (35–75) 56 (40–78) 46 (33–70) <0.001
  Onset-to-last-contrast-bolus time** 273 (209–337) 273 (222–337) 250 (198–311) 248 (192–320) 237 (189–298) <0.001
  Total number of passes†† 0 (0–3) 2 (1–4) 1 (1–3) 2 (1–3) 1 (1–2) <0.001
  Intra-arterial thrombolytics (alteplase/urokinase) 9/470 (2) 16/404 (4) 14/700 (2) 7/340 (2) 14/893 (2) 0.09
  Intraarterial nimodipine 19/470 (4) 35/404 (9) 57/700 (8) 21/340 (6) 64/893 (7) 0.04
Percentages may not total 100 due to rounding. All continuous measures are reported as median (interquartile range). Proportions are reported as n/N (%). ASPECTS 
indicates Alberta Stroke Program Early CT Score; CTA, computed tomography angiography; DBP, diastolic blood pressure; eTICI, extended Thrombolysis in Cerebral 
Infarction; EVT, endovascular treatment; ICA, internal carotid artery; ICA-T, terminal internal carotid artery; M1, middle cerebral artery segment 1; M2, middle cerebral 
artery segment 2; M3, middle cerebral artery segment 3; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and SBP, systolic blood pressure.
Missing: *13; †48; ‡78; §85; ‖92; ¶670; #247; **181; ††308.
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the occluded vessel, as opposed to it signaling a near-per-
fect angiographic result.20 Ongoing randomized clinical tri-
als such as the MR CLEAN-MED trial (ISRCTN76741621) 
will provide insight on the effect of periprocedural intra-
venously applied acetylsalicylic acid combined with or 
without low dose unfractionated heparin on improving mi-
crovascular reperfusion. Similarly, although the proportion 
of patients who received IVT before EVT in our study was 
comparable across all reperfusion grades, ongoing trials such 
as the MR CLEAN-NO IV (ISRCTN80619088), SWIFT-
DIRECT (Solitaire With the Intention for Thrombectomy 
Plus Intravenous t-PA Versus DIRECT Solitaire Stent-
Retriever Thrombectomy in Acute Anterior Circulation 
Stroke; NCT03192332), DIRECT-MT (Direct Intra-
Arterial Thrombectomy in Order to Revascularize AIS 
Patients With Large Vessel Occlusion Efficiently in Chinese 
Tertiary Hospitals: A Multicenter Randomized Clinical 
Trial; NCT03469206), and DIRECT-SAFE (A Randomized 
Controlled Trial of DIRECT Endovascular Clot Retrieval 
Versus Standard Bridging Thrombolysis With Endovascular 
Clot Retrieval; NCT03494920) will provide additional ev-
idence to whether IVT contributes to higher reperfusion 
grades or more often successful first attempts21 and, there-
fore, possibly better functional outcome. Another potential 
explanation could be related to the high proportion of eTICI 
2C patients that were treated under general anesthesia, com-
pared with other groups (37% versus 21%–29%). Although 
this may indicate that interventionists achieve better angio-
graphic outcomes in patients who lie completely still, the use 
of general anesthesia could also have negatively impacted 
functional outcome of patients.22
Conversely, an additional analysis comparing a model 
with eTICI 2C and eTICI 3 combined, to a model with eTICI 
3 as a separate category showed that the model with eTICI 
3 as a separate category did not have a statistically signifi-
cantly better fit than the model with eTICI 2C and 3 com-
bined as one category. This might imply that eTICI 2C is not 
that different from eTICI 3, and that subtle radiological sub-
divisions of reperfusion scores are not necessarily clinically 
relevant. However, more likely this analysis is underpow-
ered, as the distribution of the mRS scores shows a clear im-
provement per increasing eTICI score. Lastly, patients with 
eTICI 3 had shorter procedure times and a low number of 
passes compared with other reperfusion grades, most likely 
indicating procedures under ideal circumstances. Should 
the procedure become more complicated (and consequently 
longer), for example, due to a difficult anatomy of the carotid 
arteries or differences in thrombus characteristics and loca-
tion, perhaps it also becomes more difficult to achieve higher 
reperfusion grades.
Several limitations of our study warrant comment. First, 
while the data suggest that achieving better angiographic out-
comes beyond eTICI 2B is associated with better outcomes, 
we were not able to compare patients with eTICI 2B to 
patients who initially had eTICI 2B and in which the interven-
tionist continued to attempt to improve reperfusion. However, 
the fact that the risk of sICH appeared to decrease as reper-
fusion grade increased, suggests that reperfusion injury is 
not an issue with increasing reperfusion grade. Conversely, 
our results showed only a small absolute difference between 
eTICI 2B and eTICI 3 patients, despite being statistically 
significantly different. Although eTICI 3 produces superior 
results, only a clinical trial in which patients are randomized 
between ending EVT at eTICI 2B and continuation of EVT 
to improve beyond eTICI 2B can definitively answer whether 
the benefits of pursuing higher reperfusion grades after 2B 
outweigh the risks.
A second limitation is that not all patients in the MR 
CLEAN Registry had antero-posterior and lateral views on 
DSA imaging, thereby not meeting our inclusion criteria 
and possibly introducing unmeasured confounding in our 
patient selection. However, since eTICI grades cannot be 
reliably estimated on a single plane image,13 we felt that 
excluding these patients would lead to the lowest risk of 
Figure 2. Distribution of modified Rankin Scale (mRS) per extended Thrombolysis in Cerebral Infarction (eTICI) grade. Functional outcome per reperfusion 
grade was scored on the mRS score: a 7-point scale ranging from 0 (no disability) to 6 (death). Percentages may not total 100 due to rounding. Shift analysis 
showed an increase in odds for a better functional outcome for increasing reperfusion grade (common odds ratio [OR], 1.31 [95% CI, 1.26–1.37]; adjusted 
common OR, 1.34 [95% CI, 1.28–1.41]).
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bias. Third, we may have overestimated the proportion of 
patients with eTICI 0 to 1, as we assigned eTICI 0 to those 
patients in whom intracranial access was not achieved. This 
may have led to an overall pessimistic assessment of our 
imaging outcomes. Fourth, a recent study by Liebeskind 
et al6 further subdivided the 2B category into 2b50 (50%–
66% reperfusion) and 2b67 (67%–89% reperfusion) and 
observed clinically meaningful differences between both 
outcomes. It would have been interesting to analyze these 
categories in our data set, but unfortunately this subdi-
vided 2B category was not measured by the core labora-
tory. Lastly, operators may overestimate reperfusion grade 
compared with core laboratory observers.17 Although we 
could not make a formal comparison between local read-
ers and the core laboratory due to differences in grading 
scales, overestimation of the eTICI score by local readers 
also seems to have happened in our study (Table I in the 
Data Supplement). Such a discrepancy might affect the ex-
ternal validity of our study, as in routine practice, the local 
operator decides whether or not to continue the procedure 
and, therefore, pursue a higher reperfusion grade.
In conclusion, we found that increasing scores on the 
eTICI scale are associated with better clinical outcome in 
stroke patients who underwent EVT. This suggests that inter-
ventionists should not settle for eTICI 2B as angiographic 
target end point, but rather for the highest possible reperfu-
sion grade. Ongoing randomized clinical trials will provide 
additional insight on how to improve reperfusion for patients 
with EVT .
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Figure 3. Outcomes per extended Thrombolysis in Cerebral Infarction (eTICI) grade for better functional outcome on the modified Rankin Scale (mRS; A), 
functional independence (mRS 0–2; B), mortality (C), and symptomatic intracranial hemorrhage (sICH; D), per reperfusion grade. Adjusted (common) odds 
ratios (ORs) with 95% CIs are reported per reperfusion grade. In all analyses, eTICI 2B is used as reference category; sICH: according to the Heidelberg 
criteria.15
D
ow
nloaded from
 http://ahajournals.org by on June 5, 2020
1796  Stroke  June 2020
References
 1. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, 
Becker K, et al. Guidelines for the early management of patients with acute 
ischemic stroke: 2019 update to the 2018 guidelines for the early man-
agement of acute ischemic stroke: a guideline for healthcare profession-
als from the American Heart Association/American Stroke Association. 
Stroke. 2019;50:e344–e418. doi: 10.1161/STR.0000000000000211
 2. Turc G, Bhogal P, Fischer U, Khatri P, Lobotesis K, Mazighi M, et al. 
European Stroke Organisation (ESO) - guidelines on mechanical throm-
bectomy in acute ischemic stroke. J Neurointerv Surg. 2019;0:1–30.
 3. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, 
Demchuk AM, et al; HERMES collaborators. Endovascular thrombec-
tomy after large-vessel ischaemic stroke: a meta-analysis of individual 
patient data from five randomised trials. Lancet. 2016;387:1723–1731. 
doi: 10.1016/S0140-6736(16)00163-X
 4. Noser EA, Shaltoni HM, Hall CE, Alexandrov AV, Garami Z, 
Cacayorin ED, et al. Aggressive mechanical clot disruption: a safe ad-
junct to thrombolytic therapy in acute stroke? Stroke. 2005;36:292–296. 
doi: 10.1161/01.STR.0000152331.93770.18
 5. Goyal M, Fargen KM, Turk AS, Mocco J, Liebeskind DS, Frei D, et al. 
2C or not 2C: defining an improved revascularization grading scale and 
the need for standardization of angiography outcomes in stroke trials. J 
Neurointerv Surg. 2014;6:83–86. doi: 10.1136/neurintsurg-2013-010665
 6. Liebeskind DS, Bracard S, Guillemin F, Jahan R, Jovin TG, 
Majoie CB, et al. eTICI reperfusion: defining success in endovascular 
stroke therapy. J Neurointerv Surg 2019;11:433–438. doi: 10.1136/ 
neurintsurg-2018-014127
 7. Naragum V, Jindal G, Miller T, Kole M, Shivashankar R, 
Merino JG, et al. Functional independence after stroke thrombectomy 
using thrombolysis in cerebral infarction grade 2c: a new aim of suc-
cessful revascularization. World Neurosurg. 2018;119:e928–e933. doi: 
10.1016/j.wneu.2018.08.006
 8. Dargazanli C, Fahed R, Blanc R, Gory B, Labreuche J, Duhamel A, et al; 
ASTER Trial Investigators. Modified thrombolysis in cerebral infarction 
2C/Thrombolysis in cerebral infarction 3 reperfusion should be the aim 
of mechanical thrombectomy: insights from the ASTER Trial (Contact 
Aspiration Versus Stent Retriever for Successful Revascularization). 
Stroke. 2018;49:1189–1196. doi: 10.1161/STROKEAHA.118.020700
 9. Dekker L, Geraedts VJ, Hund H, Cannegieter SC, Nogueira RG, 
Goyal M, et al. Importance of reperfusion status after intra-arterial 
thrombectomy for prediction of outcome in anterior circulation large 
vessel stroke. Interv Neurol. 2018;7:137–147. doi: 10.1159/000486246
 10. Tung EL, McTaggart RA, Baird GL, Yaghi S, Hemendinger M, 
Dibiasio EL, et al. Rethinking thrombolysis in cerebral infarction 2b: 
which thrombolysis in cerebral infarction scales best define near complete 
recanalization in the modern thrombectomy era? Stroke. 2017;48:2488–
2493. doi: 10.1161/STROKEAHA.117.017182
 11. Jansen IGH, Mulder MJHL, Goldhoorn RB; MR CLEAN Registry inves-
tigators. Endovascular treatment for acute ischaemic stroke in routine 
clinical practice: prospective, observational cohort study (MR CLEAN 
Registry). BMJ. 2018;360:k949. doi: 10.1136/bmj.k949
 12. Compagne KCJ, Kappelhof M, Hinsenveld WH, Brouwer J, Goldhoorn 
RB, Uyttenboogaart M, et al, on behalf of the MR CLEAN Registry 
Investigators. E-Poster Discussions. Eur Stroke J. 2019;4:96–149.
 13. Gerber JC, Miaux YJ, von Kummer R. Scoring flow restoration in ce-
rebral angiograms after endovascular revascularization in acute is-
chemic stroke patients. Neuroradiology. 2015;57:227–240. doi: 
10.1007/s00234-014-1460-x
 14. Dippel DWJ, van der Worp HB, Hofmeijer J, van den Berg-Vos RM, 
van Dijk EJ, Geurts M, et al. Richtlijn herseninfarct/-bloeding. The 
Netherlands: 2018. Available at: https://richtlijnendatabase.nl/richtlijn/
herseninfarct_en_hersenbloeding/startpagina_herseninfarct_-bloeding.
html. Accessed August 30, 2018.
 15. von Kummer R, Broderick JP, Campbell BC, Demchuk A, Goyal M, 
Hill MD, et al. The heidelberg bleeding classification: classification of 
bleeding events after ischemic stroke and reperfusion therapy. Stroke. 
2015;46:2981–2986. doi: 10.1161/STROKEAHA.115.010049
 16. Tan IY, Demchuk AM, Hopyan J, Zhang L, Gladstone D, Wong K, et al. 
CT angiography clot burden score and collateral score: correlation with 
clinical and radiologic outcomes in acute middle cerebral artery infarct. 
AJNR Am J Neuroradiol. 2009;30:525–531. doi: 10.3174/ajnr.A1408
 17. Zhang G, Treurniet KM, Jansen IGH, Emmer BJ, van den Berg R, 
Marquering HA, et al; MR CLEAN Registry Investigators. Operator 
versus core lab adjudication of reperfusion after endovascular treat-
ment of acute ischemic stroke. Stroke. 2018;49:2376–2382. doi: 
10.1161/STROKEAHA.118.022031
 18. Yoo AJ, Simonsen CZ, Prabhakaran S, Chaudhry ZA, Issa MA, Fugate JE, 
et al; Cerebral Angiographic Revascularization Grading Collaborators. 
Refining angiographic biomarkers of revascularization: improving out-
come prediction after intra-arterial therapy. Stroke. 2013;44:2509–2512. 
doi: 10.1161/STROKEAHA.113.001990
 19. Marks MP, Lansberg MG, Mlynash M, Kemp S, McTaggart R, 
Zaharchuk G, et al; DEFUSE 2 Investigators. Correlation of AOL recan-
alization, TIMI reperfusion and TICI reperfusion with infarct growth 
and clinical outcome. J Neurointerv Surg. 2014;6:724–728. doi: 
10.1136/neurintsurg-2013-010973
 20. Yemisci M, Gursoy-Ozdemir Y, Vural A, Can A, Topalkara K, Dalkara T. 
Pericyte contraction induced by oxidative-nitrative stress impairs capil-
lary reflow despite successful opening of an occluded cerebral artery. Nat 
Med. 2009;15:1031–1037. doi: 10.1038/nm.2022
 21. Zaidat OO, Castonguay AC, Linfante I, Gupta R, Martin CO, Holloway WE, 
et al. First pass effect: a new measure for stroke thrombectomy devices. 
Stroke. 2018;49:660–666. doi: 10.1161/STROKEAHA.117.020315
 22. Campbell BCV, van Zwam WH, Goyal M, Menon BK, Dippel DWJ, 
Demchuk AM, et al; HERMES collaborators. Effect of general anaes-
thesia on functional outcome in patients with anterior circulation isch-
aemic stroke having endovascular thrombectomy versus standard care: a 
meta-analysis of individual patient data. Lancet Neurol. 2018;17:47–53. 
doi: 10.1016/S1474-4422(17)30407-6
D
ow
nloaded from
 http://ahajournals.org by on June 5, 2020
